[Glycemic control and cardiovascular benefit: what do we know today?]

Dtsch Med Wochenschr. 2011 May;136(19):1027; author reply 1027-8. doi: 10.1055/s-0031-1275838. Epub 2011 May 3.
[Article in German]
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • Age Factors
  • Biomarkers
  • Cardiovascular Diseases / blood*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / mortality
  • Early Termination of Clinical Trials
  • Glycated Hemoglobin / metabolism*
  • Humans
  • Hypoglycemia / blood
  • Hypoglycemia / complications
  • Hypoglycemia / mortality
  • Hypoglycemic Agents / therapeutic use
  • Middle Aged
  • Pioglitazone
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Rosiglitazone
  • Survival Analysis
  • Thiazolidinediones / therapeutic use

Substances

  • Biomarkers
  • Glycated Hemoglobin
  • Hypoglycemic Agents
  • Pioglitazone
  • Rosiglitazone
  • Thiazolidinediones
  • hemoglobin A1c protein, human